{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T16:16:32Z","timestamp":1781108192646,"version":"3.54.1"},"reference-count":22,"publisher":"Japanese Society for Pediatric Endocrinology","issue":"2","funder":[{"name":"Morinaga Foundation for Health & Nutrition","award":["No.16"],"award-info":[{"award-number":["No.16"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Pediatr Endocrinol"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1297\/cpe.2025-0102","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T22:07:54Z","timestamp":1770242874000},"page":"161-167","source":"Crossref","is-referenced-by-count":0,"title":["Clinical utility of TRAb reduction in predicting remission in pediatric Graves\u2019 disease"],"prefix":"10.1297","volume":"35","author":[{"given":"Shintaro","family":"Terashita","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Faculty of Medicine, University of Toyama, Toyama, Japan"},{"name":"Division of Endocrinology and Metabolism, National Center for Child Health and Development, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Nagamori","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Faculty of Medicine, University of Toyama, Toyama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Naiki","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, National Center for Child Health and Development, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiko","family":"Sugiura","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, National Center for Child Health and Development, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagisa","family":"Ujita","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, National Center for Child Health and Development, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Kashimada","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, National Center for Child Health and Development, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chihaya","family":"Imai","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Faculty of Medicine, University of Toyama, Toyama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"125","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Smith, TJ, Heged\u00fcs, L. Graves\u2019 disease. N Engl J Med 2016;375: 1552\u201365.","DOI":"10.1056\/NEJMra1510030"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Bartalena, L. Diagnosis and management of Graves disease: a global overview. Nat Rev Endocrinol 2013;9: 724\u201334.","DOI":"10.1038\/nrendo.2013.193"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Conrad, N, Misra, S, Verbakel, JY, Verbeke, G, Molenberghs, G, Taylor, PN, et al. Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK. Lancet 2023;401: 1878\u201390.","DOI":"10.1016\/S0140-6736(23)00457-9"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Xie, H, Chen, D, Zhang, J, Yang, R, Gu, W, Wang, X. Characteristics of Graves\u2019 disease in children and adolescents in Nanjing: A retrospective investigation study. Front Public Health 2022;10: 993733.","DOI":"10.3389\/fpubh.2022.993733"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. L\u00e9ger, J, Oliver, I, Rodrigue, D, Lambert, AS, Coutant, R. Graves\u2019 disease in children. Ann Endocrinol (Paris) 2018;79: 647\u201355.","DOI":"10.1016\/j.ando.2018.08.001"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Cui, Y, Chen, J, Guo, R, Yang, R, Chen, D, Gu, W, et al. Relapse of Graves\u2019 disease in Chinese children: a retrospective cohort study. Eur Thyroid J 2023;12: e230018.","DOI":"10.1530\/ETJ-23-0018"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. van Lieshout, JM, Mooij, CF, van Trotsenburg, ASP, Zwaveling-Soonawala, N. Methimazole-induced remission rates in pediatric Graves\u2019 disease: a systematic review. Eur J Endocrinol 2021;185: 219\u201329.","DOI":"10.1530\/EJE-21-0077"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8. Ross, DS, Burch, HB, Cooper, DS, Greenlee, MC, Laurberg, P, Maia, AL, et al. 2016 American Thyroid Association Guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 2016;26: 1343\u2013421.","DOI":"10.1089\/thy.2016.0229"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Lee, YJ. Updates in the management of Graves disease in children. Ewha Med J 2023;46(Suppl 1): e31.","DOI":"10.12771\/emj.2023.e31"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. Orgiazzi, J, Madec, AM. Reduction of the risk of relapse after withdrawal of medical therapy for Graves\u2019 disease. Thyroid 2002;12: 849\u201353.","DOI":"10.1089\/105072502761016467"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Karmisholt, J, Andersen, SL, Bulow-Pedersen, I, Carl\u00e9, A, Krejbjerg, A, Nygaard, B. Predictors of initial and sustained remission in patients treated with antithyroid drugs for Graves\u2019 hyperthyroidism: the RISG Study. J Thyroid Res 2019;2019: 5945178.","DOI":"10.1155\/2019\/5945178"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Barbesino, G, Tomer, Y. Clinical review: Clinical utility of TSH receptor antibodies. J Clin Endocrinol Metab 2013;98: 2247\u201355.","DOI":"10.1210\/jc.2012-4309"},{"key":"13","unstructured":"13. Wakui, Y, Suzuki, N, Uemichi, F, Sakai, H, Odawara, M, Fukutake, K. Basic and clinical evaluation of Elecsys anti-TSHR for thyrotropin receptor antibody (TRAb). J Tokyo Med Univ 2011;69: 382\u20138."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Rho, JG, Kum, CD, Seo, YJ, Shim, YS, Lee, HS, Hwang, JS. Long-term outcomes of Graves\u2019 disease in children and adolescents receiving antithyroid drugs. Ann Pediatr Endocrinol Metab 2021;26: 266\u201371.","DOI":"10.6065\/apem.2040286.143"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15. Glaser, NS, Styne, DM, Organization of Pediatric Endocrinologists of Northern California Collaborative Graves\u2019 Disease Study Group. Predicting the likelihood of remission in children with Graves\u2019 disease: a prospective, multicenter study. Pediatrics 2008;121: e481\u20138.","DOI":"10.1542\/peds.2007-1535"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Gastaldi, R, Poggi, E, Mussa, A, Weber, G, Vigone, MC, Salerno, M, et al. Graves disease in children: thyroid-stimulating hormone receptor antibodies as remission markers. J Pediatr 2014;164: 1189\u20131194.e1.","DOI":"10.1016\/j.jpeds.2013.12.047"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. St\u00f6hr, M, Oeverhaus, M, Lytton, SD, Horstmann, M, Zwanziger, D, M\u00f6ller, L, et al. Predicting the relapse of hyperthyroidism in treated Graves\u2019 disease with orbitopathy by serial measurements of TSH-receptor autoantibodies. Horm Metab Res 2021;53: 235\u201344.","DOI":"10.1055\/a-1373-5523"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Cappelli, C, Gandossi, E, Castellano, M, Pizzocaro, C, Agosti, B, Delbarba, A, et al. Prognostic value of thyrotropin receptor antibodies (TRAb) in Graves\u2019 disease: a 120 months prospective study. Endocr J 2007;54: 713\u201320.","DOI":"10.1507\/endocrj.K06-069"},{"key":"19","doi-asserted-by":"publisher","unstructured":"19. Ohye, H, Minagawa, A, Noh, JY, Mukasa, K, Kunii, Y, Watanabe, N, et al. Antithyroid drug treatment for graves\u2019 disease in children: a long-term retrospective study at a single institution. Thyroid 2014;24: 200\u20137.","DOI":"10.1089\/thy.2012.0612"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. L\u00e9ger, J, Gelwane, G, Kaguelidou, F, Benmerad, M, Alberti, C, French Childhood Graves\u2019 Disease Study Group. Positive impact of long-term antithyroid drug treatment on the outcome of children with Graves\u2019 disease: national long-term cohort study. J Clin Endocrinol Metab 2012;97: 110\u20139.","DOI":"10.1210\/jc.2011-1944"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Meisel, A, Baggi, F, Behin, A, Evoli, A, Kostera-Pruszczyk, A, Mantegazza, R, et al. Role of autoantibody levels as biomarkers in the management of patients with myasthenia gravis: A systematic review and expert appraisal. Eur J Neurol 2023;30: 266\u201382.","DOI":"10.1111\/ene.15565"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Wong, TWC, Wong, MYS. Remission in pediatric Graves\u2019 disease treated with antithyroid drug and the risk factors associated with relapse. Ann Pediatr Endocrinol Metab 2022;27: 308\u201314.","DOI":"10.6065\/apem.2244038.019"}],"container-title":["Clinical Pediatric Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/cpe\/35\/2\/35_2025-0102\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T04:25:09Z","timestamp":1775276709000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/cpe\/35\/2\/35_2025-0102\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1297\/cpe.2025-0102","relation":{},"ISSN":["0918-5739","1347-7358"],"issn-type":[{"value":"0918-5739","type":"print"},{"value":"1347-7358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"2025-0102"}}